[1]
Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in Parkinson’s disease: focus on anti-Parkinsonian drugs. Curr Drug Ther 2015; 10: 66-81.
[2]
Garzorz N. Extrapyramidales System.In: Neuroanatomie; Garzoz N. Elsevier: München 2009; pp. 120-1.
[3]
Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanism in Parkinson’s disease. Neurology 1998; 39: 7-11.
[4]
Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in Parkinson’s disease: an enlarged neural network. Basal Ganglia 2011; 1: 17.
[5]
Ansah TA, Ferguson MD, Nayyar T. The 5-HT(2A) receptor antagonist M-100,907 produces antiparkinsonian effects and decreases striatal glutamate. Front Syst Neurosci 2011; 5: 48.
[6]
Liu QR, Canseco-Alba A, Zhang HY, et al. Cannabinoid type 2 receptors in dopamine neurons inhibit psychomotor behaviors, alters anxiety, depression and alcohol preference. Sci Rep 2017; 7: 17410.
[7]
Werner FM, Coveñas R. Vergleich einer monodopaminergen Pharmakotherapie miteiner multimodalen Pharmakotherapie des Morbus Parkinson. Neurol Rehabil 2017; (Suppl. 1)S47-8.
[8]
Berlanga ML, Simpson TK, Alcantara AA. Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: a potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release. J Comp Neurol 2005; 492: 34-49.
[9]
Werner FM, Coveñas R. Assessments in primary Parkinson syndrome for comparison between mono-dopaminergic and multi-target anti-Parkinsonian pharmacotherapies. J Med Diagn Meth 2017; 6: 2.
[10]
Pérez LM, Farricis C, Puente V, Planas J, Ruiz J. The use of subcutaneous scopolamine as a palliative treatment in Parkinson’s disease. Palliat Med 2011; 25: 92-3.
[11]
Huang LZ, Grady SR, Quik M. Nicotine reduces L-DOPA-induced dyskinesia by acting at beta2* nicotinic receptors. J Pharmacol Exp Ther 2011; 338: 932-41.
[12]
Riahi G, Morissette M, Parent M, Di Paolo T. Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesia. Eur J Neurosci 2011; 33: 1823-31.
[13]
Markham A. Pimavanserin: a first global approval. Drugs 2016; 76: 1053-7.
[14]
Fergusson MC, Nayyar T, Ansah TA. Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson’s disease. Neurochem Int 2014; 71: 36-46.
[15]
Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson’s disease therapeutics. Mov Disord 2011; 26: 1072-82.
[16]
Diguid IC, Smart TG. Presynaptic NMDA receptors. J Neurosci 2010; 30: 14440-5.
[17]
Huang YH, Ishikawa M, Lee BR, Nakanishi N, Schlüter OM, Dong Y. Searching for presynaptic NMDA receptors in the nucleus accumbens. J Neurosci 2011; 31: 8453-63.
[18]
Lindemann L, Jaeschke G, Michalon A, et al. CTEP: a novel, potent, long-acting and orally bioavialable mGlu5 inhibitor. J Pharmacol Exp Ther 2011; 339: 474-86.
[19]
Ammari R, Bioulac B, García DF, Hammond C. The subthalamic nucleus becomes a generator in the dopamine-depleted state. Its high frequency stimulation dramatically weakesn transmission to the globus pallidus. Front Syst Neurosci 2011; 4: 43.
[20]
Gajcy K, Lochynski S, Librowski T. A role of GABA analogues in the treatment of neurological diseases. Curr Med Chem 2010; 17: 2338-47.
[21]
Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 2003; 61: S32-8.
[22]
Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. The effect of istradefylline for Parkinson’s disease: a meta-analysis. Sci Rep 2017; 7: 18018.
[23]
Bogenpohl JW, Ritter SL, Hall RA, Smith Y. Adenosine A(2A) receptor in the monkey basal ganglia: ultrastructural localization and co-localization with the metabotropic glutamate receptor 5 in the striatum. J Comp Neurol 2012; 520: 570-89.
[24]
Lim K, See YM, Lee J. A Systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 2017; 15: 301-12.
[25]
Shi J, Cai Q, Zhang J, He X, Liu Y, Zhu R, et al. AM-1,241 alleviates MPTP-induced Parkinson’s disease and promotes the regeneration of DA in PD mice. Oncotarget 2017; 8: 87837-50.
[26]
McGinty JF. Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog Brain Res 2007; 160: 273-84.
[27]
Buxton D, Bracci E, Overton PG, Gurney K. Striatal neuropeptides enhance selection and rejection of sequential actions. Front Comput Neurosci 2017; 11: 62.
[28]
Ljundahl A, Hanrieder J, Fälth M, Bergquist J, Andersson M. Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson’s disease. PLoS One 2011; 6e25653
[29]
Antonelli T, Tomasini MC, Finetti S, et al. Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture. J Neurosci Res 2002; 70: 766-73.
[30]
Thornton E, Tran TT, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 2010; 481: 64-7.
[31]
Govindaiah G, Wang Y, Cox L. Substance selectively modulates GABA(A) receptor-mediated synaptic transmission in striatal cholinergic interneurons. Neuropharmacology 2010; 58: 413-22.
[32]
Herring WJ, Assaid C, Budd K, et al. A Phase Ib randomized controlled study to evaluate the effectiveness of a single-dose of the NR2B selective N-Methyl-D-Aspartate antagonist MK-657 on levodopa-induced dyskinesias and motor symptoms in patients with Parkinson disease. Clin Neuropharmacol 2017; 40: 255-60.
[33]
Michel A, Nicolas JM, Rose S, et al. Antiparkinsonian effects of the “Radiprodil and Tozadenant” combination in MPTP-treated marmosets. PLoS One 2017; 12e0182887
[34]
Fergusson MC, Nayyar T, Deutch AY, Ansah TA. 5-HT2A receptor antagonists improve motor impairments in MPTP mouse model of Parkinson’s disease. Neuropharmacology 2010; 59: 31-6.
[35]
Werner FM, Coveñas R. Classical neurotransmitter and neuropeptides involved in schizophrenia: how to choose the appropriate antipsychotic drug? Curr Drug Ther 2013; 8: 132-43.
[36]
Wang X, Han C, Xu Y, et al. Synthesis and evaluation of phenylxanthine derivates as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules 2017; 22: pii:E1010
[37]
Maranis S, Stamatis D, Tsironis C, Konitsiotis S. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamte receptors antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia. Eur J Pharmacol 2012; 683: 71-7.
[38]
Litim N, Morissette M, Di Paolo T. Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: an update from the last 5 years of research. Neuropharmacology 2017; 115: 166-79.
[39]
Kataoka H, Sawada Y, Namizaki T, Shimozato N, Yoshiji H, Ueno S. Intrajejunal infusion of levodopa-carbidopa gel can continuously reduce the severity of dropped head in Parkinson’s disease. Front Neurol 2017; 8: 547.
[40]
Millage B, Vesey E, Finkelstein M, Anheluk M. Effect on gait speed, balance, motor symptom rating, and quality of life in those with stage I Parkinson’s disease utilizing LSVT BIGR. Rehabil Res Pract 2017; 20179871070
[41]
FitzGerald JJ, Lu Z, Jarenosettasin P, Antoniades CA. Quantifying motor impairment in movement disorders. Front Neurosci 2018; 12: 202.
[42]
Wyman-Chick KA, Martin PK, Barrett MJ, Manning CA, Sperling SA. Diagnostic accuracy and confidence in the clinical detection of cognitive impairment in early-stage Parkinson disease. J Geriatr Psychiatry Neurol 2017; 30: 178-83.
[43]
Katunina E, Titova N. The epidemiology of non-motor symptoms in Parkinson’s disease (cohort and other studies). Int Rev Neurobiol 2017; 91-110.
[44]
Saeed U, Compagnone J, Aviv RJ, et al. Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodener 2017; 28: 6-8.
59
2
1
1